leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...3031323334353637383940...235236»
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  An autopsy case of alpha-fetoprotein-producing large duodenal adenocarcinoma. (Pubmed Central) -  Nov 27, 2023   
    Duodenal cancer is rare, and AFP-producing duodenal cancer is even rarer, with only 21 reported cases, including our own. We present this autopsy case of AFP-producing duodenal adenocarcinoma and review the cases reported in the relevant literature.
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial completion date, Trial primary completion date, Metastases:  NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer (clinicaltrials.gov) -  Nov 27, 2023   
    P2,  N=200, Recruiting, 
    We present this autopsy case of AFP-producing duodenal adenocarcinoma and review the cases reported in the relevant literature. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2023
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Review, Journal:  Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives. (Pubmed Central) -  Nov 25, 2023   
    However, many significant problems are still being experienced with these treatments, mainly off-target effects, toxic side effects, and the associated therapeutic failures of small molecular drugs and the rapid loss of efficacy of mAb therapies. Other novel delivery strategies continue to be investigated, including ligand-based targeting of CRC cells.
  • ||||||||||  Preclinical, Journal, Circulating tumor cells, Tumor cell:  Mobilization of Circulating Tumor Cells after Short- and Long-Term FOLFIRINOX and GEM/nab-PTX Chemotherapy in Xenograft Mouse Models of Human Pancreatic Cancer. (Pubmed Central) -  Nov 25, 2023   
    In this study, we sequentially examined CTC numbers after single-dose and repetitive-dose chemotherapy, including FORFIRINOX (FFX) and Gemcitabine and nab-Paclitaxel (GnP) using two pancreatic cancer xenograft models...These findings indicate that mobilization of CTCs early after chemotherapy is mediated by the shedding of degenerated tumor cells into the disrupted blood vessels driven by the pure destructive histological changes in primary tumor tissues. These results suggest that sequential CTC monitoring during chemotherapy can be a useful liquid biopsy diagnostic tool to predict tumor chemosensitivity and resistance in preclinical and clinical settings.
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
    Retrospective data, Journal, Metastases:  Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study. (Pubmed Central) -  Nov 22, 2023   
    Our findings show that triplet-drug chemotherapy (FOLFOXIRI) combined with anti-EGFR antibody (panitumumab or cetuximab) represents a very effective therapeutic combination associated with a significant ORR and R0 rection rate for patients with molecularly unselected and surgically unresectable metastatic CRC. The efficacy and safety of nal-IRI?+?5-FU/LV for patients with PDAC are not significantly different for those aged???70
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Metastases:  Immune checkpoint inhibitors in BRAF-mutated advanced colorectal cancer. (Pubmed Central) -  Nov 22, 2023   
    More importantly, this work BRAF-mutated advanced colorectal cancer is a demanding entity that does not respond to standard chemotherapy regimens (FOLFOX, capecitabine)
  • ||||||||||  dalutrafusp alfa (AGEN1423) / Agenus
    Phase classification, Combination therapy, Monotherapy, Metastases:  Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Nov 21, 2023   
    P1,  N=22, Terminated, 
    Trial completion date: Oct 2023 --> May 2025 | Trial primary completion date: May 2023 --> Dec 2024 Phase classification: P1a/1b --> P1
  • ||||||||||  Natrunix (vilamakitug) / XBiotech
    Enrollment closed, Trial completion date, Trial primary completion date:  1-BETTER: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer (clinicaltrials.gov) -  Nov 18, 2023   
    P1/2,  N=69, Active, not recruiting, 
    Not yet recruiting --> Recruiting | N=25 --> 3 Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> May 2024 | Trial primary completion date: Jul 2023 --> Feb 2024
  • ||||||||||  oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
    Phase classification, Trial termination, Combination therapy, Metastases:  COLUMBIA 1: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC (clinicaltrials.gov) -  Nov 15, 2023   
    P1/2,  N=61, Terminated, 
    Phase classification: P1a/1b --> P1 Phase classification: P1b/2 --> P1/2 | Completed --> Terminated; On 17 February 2022, the decision was made to terminate the clinical study because superior efficacy was not observed for the novel study drug combinations under investigation.
  • ||||||||||  Avastin (bevacizumab) / Roche, Kaitanni (cadonilimab) / Akesobio
    Enrollment open, Trial initiation date, Combination therapy, Metastases:  Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer (clinicaltrials.gov) -  Nov 15, 2023   
    P2,  N=20, Recruiting, 
    Phase classification: P1b/2 --> P1/2 | Completed --> Terminated; On 17 February 2022, the decision was made to terminate the clinical study because superior efficacy was not observed for the novel study drug combinations under investigation. Not yet recruiting --> Recruiting | Initiation date: May 2023 --> Nov 2023
  • ||||||||||  Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly
    Trial primary completion date:  FIRE-6: FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC (clinicaltrials.gov) -  Nov 14, 2023   
    P2,  N=57, Active, not recruiting, 
    Trial primary completion date: Nov 2022 --> Nov 2023 Trial primary completion date: Aug 2022 --> Nov 2023
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Journal, HEOR, Real-world evidence, Real-world, Metastases:  Real?world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real?world data project. (Pubmed Central) -  Nov 13, 2023   
    From the Tokushukai REAl-world Data project, 1,093 patients with metastatic pancreatic cancer treated with gemcitabine, tegafur/gimeracil/oteracil (S-1), gemcitabine plus S-1, gemcitabine plus nab-paclitaxel, or fluorouracil, folic acid, oxaliplatin and irinotecan (FOLFIRINOX) between April 2010 and March 2020 were identified...In summary, the real-world data indicated that standard care, including chemotherapy, for metastatic pancreatic cancer was widely used in hospitals throughout Japan and verified the survival benefits of gemcitabine plus nab-paclitaxel and FOLFIRINOX observed in prior clinical trials. This trial has been registered in the University Hospital Medical Information Network Clinical Trials Registry as UMIN000050590 on April 1, 2023.